Rational in silico design and synthetic route elaboration for anti-RCC benzimidazole candidates

Abstract: Benzimidazole continues to be an intriguing scaffold in recent drug discovery, owing to its broad spectrum of pharmacological effects. In recent years, a variety of its derivatives, which included chalcone imines, hydrazones, and thiosemicarbazones, were actively investigated for their antitumor potential. In the search for new agents capable of treating kidney cancer, an analysis of a small series of 2-substituted benzimidazoles (45) using 3D-QSAR modelling was performed to determine the antiproliferative activities against cancer cell lines A-498. The biological activity was sufficient to establish a meaningful structure–activity relationship, providing a foundation for the design of more potent compounds. The activity-favouring and activity-disfavoring structural regions were clearly revealed using contour maps generated by the models. The CoMSIA/SHD model was one of the best developed, and its high statistical robustness (q2 = 0.751) and predictive power (R2 pred = 0.924) indicated its reliability. We designed five new derivatives of benzimidazole based on the QSAR results, which demonstrated potent inhibitory potential. Molecular docking studies were performed in order to investigate in detail their interaction modes with the aromatic receptor, and stable binding conformations at the active site have been found. The in silico pharmacokinetic studies suggested that these compounds have a favourable ADMET and bioavailability profile, reinforcing their suitability for in vitro testing. Two leads, L15 and L22, with better PKs properties and high-predicted activities, were subjected to a 100-ns MD simulation in complex with the aromatase target to investigate their stability. We also conducted a retrosynthetic analysis for L15 and L22, suggesting potential synthetic routes for experimental validation. Overall, these findings suggest that benzimidazole analogues could be promising candidates for treating RCC and possibly for blocking aromatase.

How to cite this paper

 Mchichi, L., Alaqarbeh, M & Bouachrine, M. (2025). Rational in silico design and synthetic route elaboration for anti-RCC benzimidazole candidates.Current Chemistry Letters, 14(4), 743-770.

Refrences

1. Siegel R. L., Giaquinto A. N., and Jemal A. (2024) Cancer statistics, 2024. CA: CA Cancer J Clin., 74 (1) 12–49. 2. Fares J., Fares M. Y., Khachfe H. H., Salhab H. A., and Fares Y. (2020) Molecular principles of metastasis: A hallmark of cancer revisited. Sig Transduct Target Ther., 5 (1) 28. 3. Bahadoram S., Davoodi M., Hassanzadeh S., Bahadoram M., Barahman M., and Mafakher L. (2022) Renal cell carcinoma: An overview of the epidemiology, diagnosis, and treatment. G Ital Nefrol., 39 (3) 2022. 4. Motzer R. J., Jonasch E., Agarwal N., Alva A., Bagshaw H., Baine M., Beckermann K., Carlo M. I., Choueiri T. K., and Costello B. A. (2024) Nccn guidelines® insights: Kidney cancer, version 2.2024: Featured updates to the nccn guidelines. J. Natl. Compr. Cancer Netw., 22 (1) 4–16. 5. Yeh S., Xu H., Hu Y., Yang G., Joseph J., and Messing E. M. (2024) Pd51-10 estrogen receptor signals promote autophagy and m2 macrophage polarization in the tki-resistant rcc. J. Urol., 211 (5S) e1069. 6. Ding J., Cui X.-G., Chen H.-J., Sun Y., Yu W.-W., Luo J., Xiao G.-Q., Chang C., Qi J., and Yeh S. (2022) Targeting circdgkd intercepts tki’s effects on up-regulation of estrogen receptor β and vasculogenic mimicry in renal cell carcinoma. Cancers, 14 (7) 1639. 7. Correia De Sousa M., Delangre E., Türkal M., Foti M., and Gjorgjieva M. (2023) Endoplasmic reticulum stress in renal cell carcinoma. Int. J. Mol. Sci., 24 (5) 4914. 8. Pontes O., Oliveira-Pinto S., Baltazar F., and Costa M. (2022) Renal cell carcinoma therapy: Current and new drug candidates. Drug Discov. Today, 27 (1) 304–314. 9. Bouzian Y., El Hafi M., Parvizi N., Kim W., Subaşioğlu M., Ozcan M., Turkez H., and Mardinoglu A. (2024) Design and evaluation of novel inhibitors for the treatment of clear cell renal cell carcinoma. Bioorg. Chem., 151 (2024) 107597. 10. Song M. (2017) Recent developments in small molecule therapies for renal cell carcinoma. Eur. J. Med. Chem., 142 (2017) 383–392. 11. Ashaq A., Maqbool M. F., Maryam A., Khan M., Shakir H. A., Irfan M., Qazi J. I., Li Y., and Ma T. (2021) Hispidulin: A novel natural compound with therapeutic potential against human cancers. Phytother. Res., 35 (2) 771–789. 12. Kousar R., Naeem M., Jamaludin M. I., Arshad A., Shamsuri A. N., Ansari N., Akhtar S., Hazafa A., Uddin J., and Khan A. (2022) Exploring the anticancer activities of novel bioactive compounds derived from endophytic fungi: Mechanisms of action, current challenges and future perspectives. Am. J. Cancer Res., 12 (7) 2897. 13. El-Deek H. E., Ahmed A. M., Hassan T. S., and Morsy A. M. (2018) Expression and localization of estrogen receptors in human renal cell carcinoma and their clinical significance. Int. J. Clin. Exp. Pathol, 11 (6) 3176. 14. El Mchichi L., Tabti K., Kasmi R., El-Mernissi R., El Aissouq A., En-Nahli F., Belhassan A., Lakhlifi T., and Bouachrine M. (2022) 3d-qsar study, docking molecular and simulation dynamic on series of benzimidazole derivatives as anti-cancer agents. J. Indian Chem. Soc., 99 (9) 100582. 15. Gaba M., and Mohan C. (2016) Development of drugs based on imidazole and benzimidazole bioactive heterocycles: Recent advances and future directions. Med. Chem. Res., 25, 173–210. 16. Ebenezer O., Oyetunde-Joshua F., Omotoso O. D., and Shapi M. (2023) Benzimidazole and its derivatives: Recent advances (2020–2022). Results Chem., 5 (2023) 100925. 17. Sadowski M., Dresler E., Zawadzińska K., Wróblewska A., and Jasiński R. (2024) Syn-propanethial s-oxide as an available natural building block for the preparation of nitro-functionalized, sulfur-containing five-membered heterocycles: An medt study. Molecules, 29 (20) 4892. 18. Sadowski M., and Kula K. (2024) Unexpected course of reaction between (1e, 3e)-1, 4-dinitro-1, 3-butadiene and n-methyl azomethine ylide—a comprehensive experimental and quantum-chemical study. Molecules, 29 (21) 5066. 19. Yadav G., and Ganguly S. (2015) Structure activity relationship (sar) study of benzimidazole scaffold for different biological activities: A mini-review. Eur. J. Med. Chem., 97, 419–443. 20. Solmaz B., Oguz A., Oguz M., Ozturk B., and Yilmaz M. (2025) Synthesis, anticancer activity, and mitochondria-targeted bioimaging applications of novel fluorescent calix [4] arenes-benzimidazole derivatives. Curr Med Chem. 21. Kabi A. K., Sravani S., Gujjarappa R., Garg A., Vodnala N., Tyagi U., Kaldhi D., Singh V., Gupta S., and Malakar C. C. (2022) An overview on biological activity of benzimidazole derivatives. Nanostruct. Biomater.: Basic Struc. and App., 351–378. 22. El Mchichi L., Aouidate A., Chokrafi F. Z., Ghaleb A., Khalil F., Lakhlifi T., and Bouachrine M. (2018) Prediction of biological activity of pyrazolo [3, 4-b] quinolinyl acitamide by qsar results. RHAZES: Green and Appl. Chem., 3 (3) 79–93. 23. Tabti K., Elmchichi L., Sbai A., Maghat H., Bouachrine M., Lakhlifi T., and Ghosh A. (2022) In silico design of novel pin1 inhibitors by combined of 3d-qsar, molecular docking, molecular dynamic simulation and admet studies. J. Mol. Struct., 1253, 132291. 24. Zrinej J., Elmchichi L., Alaqarbeh M., Lakhlifi T., and Bouachrine M. (2023) Computational approach: 3d-qsar, molecular docking, admet, molecular dynamics simulation investigations, and retrosynthesis of some curcumin analogues as parp-1 inhibitors targeting colon cancer. New J. Chem., 47 (45) 20987–21009. 25. Kasmi R., Elmchichi L., El Aissouq A., Bouachrine M., and Ouammou A. (2021) In silico drug design: Development of new pyrimidine-based benzothiazole derivatives, selective for cdk2. Lett. Drug Des. Discov., 18 (10) 961–975. 26. El Mchichi L., Bouachrine M., and Lakhlifi T. (2025) Anticancer activity in heterocyclic organic structures: A pathway to novel drug development part 1. 1 (1st ed.). CRC Press. https://doi.org/10.1201/9781003653134. 27. Zrinej J., Ouabane M., El Mchichi L., Qara A., Sekkate C., Lakhlifi T., and Bouachrine M. (2025) Chemical and biological evaluation of the plumbago zeylanica plant against prostate cancer. A unified approach combining molecular docking, dynamic simulations, pharmacophore modeling, dft and admet studies. Vietn. J. Chem. 28. Soudani W., Zaki H., Alaqarbeh M., Elmchichi L., Bouachrine M., and Hadjadj-Aoul F. Z. (2023) Discover the medication potential of algerian medicinal plants against sars-cov-2 main protease (mpro): Molecular docking, molecular dynamic simulation, and admet analysis. Chem. Afr., 6 (6) 2879–2895. 29. Zaki R. M., El-Dean A. M. K., Radwan S. M., and Saber A. F. (2018) A convenient synthesis, reactions and biological activity of some new 6h-pyrazolo [4', 3': 4, 5] thieno [3, 2-d][1, 2, 3] triazine compounds as antibacterial, anti-fungal and anti-inflammatory agents. J. Braz. Chem. Soc., 29 (12) 2482–2495. 30. Zaki R. M., Saber A. F., El-Dean A. M. K., and Radwan S. M. (2020) A concise review on synthesis, reactions and biological importance of thienopyrazoles. Arkivoc, 2020 (1) 20–60. 31. Saber A. F., Zaki R. M., Kamal El‐Dean A. M., and Radwan S. M. (2020) Synthesis, reactions, and spectral characterization of some new biologically active compounds derived from thieno [2, 3‐c] pyrazole‐5‐carboxamide. J. Heter. Chem., 57 (1) 238–247. 32. El-Dean A. M. K., Zaki R. M., Radwan S., and Saber A. F. (2017) Synthesis, reactions and spectral characterization of novel thienopyrazole derivatives. Eur. Chem. Bull, 6 (12) 550–553. 33. Fouada M. R., El-Aswada A. F., Alya M. I., and Badawya M. E. (2023) Curr. chem. lett., 13 (2024) 503–514. 34. Abdel-Raheem S. A., Fouad M. R., Gad M. A., El-Dean A. M. K., and Tolba M. S. (2023) Environmentally green synthesis and characterization of some novel bioactive pyrimidines with excellent bioefficacy and safety profile towards soil organisms. J. Environ. Chem. Eng., 11 (5) 110839. 35. Ersan R. H., Kuzu B., Yetkin D., Alagoz M. A., Dogen A., Burmaoglu S., and Algul O. (2022) 2-phenyl substituted benzimidazole derivatives: Design, synthesis, and evaluation of their antiproliferative and antimicrobial activities. Med. Chem. Res., 31 (7) 1192–1208. 36. Elmchichi L., Belhassan A., Aouidate A., Ghaleb A., Lakhlifi T., and Bouachrine M. (2020) Qsar study of new compounds based on 1, 2, 4-triazole as potential anticancer agents. Ph. Chem. Res., 8 (1) 125–137. 37. Nepali K., Sharma S., Sharma M., Bedi P., and Dhar K. (2014) Rational approaches, design strategies, structure activity relationship and mechanistic insights for anticancer hybrids. Eur. j. med. chem., 77, 422–487. 38. Elmchichi L., Belhassan A., Lakhlifi T., and Bouachrine M. (2020) 3d‐qsar study of the chalcone derivatives as anticancer agents. J. Chem., 2020 (1) 5268985. 39. Alaqarbeh M., El Mchichi L., Abouzied A. S., Bouzzine S. M., Huwaimel B., and Bouachrine M. (2023) Computational investigation of structural-biological inhibitory activity for au (iii) porphyrin complexes against mcf-7 human breast cancer. Chem. Data Collec., 48, 101094. 40. Chtita S., Aouidate A., Belhassan A., Ousaa A., Taourati A. I., Elidrissi B., Ghamali M., Bouachrine M., and Lakhlifi T. (2020) Qsar study of n-substituted oseltamivir derivatives as potent avian influenza virus h5n1 inhibitors using quantum chemical descriptors and statistical methods. New J. Chem., 44 (5) 1747–1760. 41. Clark M., Cramer Iii R. D., and Van Opdenbosch N. (1989) Validation of the general purpose tripos 5.2 force field. J. comput. chem., 10 (8) 982–1012. 42. Soukaina E., Al-Zaqri N., Warad I., Ichou H., Yassine K., Guenoun F., and Bouachrine M. (2023) Novel antiproliferative inhibitors from salicylamide derivatives with dipeptide moieties using 3d-qsar, molecular docking, molecular dynamic simulation and admet studies. J. Mol. Struct., 1282, 135219. 43. Wold S., (1991). Validation of QSAR’s. Quant Struct Relatsh 10: 191–193. 44. Cruciani G., Baroni M., Clementi S., Costantino G., Riganelli D., and Skagerberg B. (1992) Predictive ability of regression models. Part i: Standard deviation of prediction errors (sdep). J. Chemometr., 6 (6) 335–346. 45. Roy K., Das R. N., Ambure P., and Aher R. B. (2016) Be aware of error measures. Further studies on validation of predictive qsar models. Chemometr. Intell. Lab. Syst., 152, 18–33. 46. Tropsha A., Gramatica P., and Gombar V. K. (2003) The importance of being earnest: Validation is the absolute essential for successful application and interpretation of qspr models. QSAR & Combina. Sc., 22 (1) 69–77. 47. Reda E.-M., Khatabi K. E., Khaldan A., Bouamrane S., Elmchichi L., Ajana M. A., Lakhlifi T., and Bouachrine M. (2022) 3d-qsar, admet and docking studies for design new 5, 5-diphenylimidazolidine-2, 4-dione derivatives agents against cervical cancer. Orbital: Electron. J. Chem., 24–32. 48. El Mchichi L., Alaqarbeh M., Lakhlifi T., and Bouachrine M. (2024) Discovery of a new isatin scaffold for bcr‐abl tyrosine kinase inhibitors using a comprehensive computational approach. ChemistrySelect, 9 (43) e202402053. 49. Golbraikh A., and Tropsha A. (2002) Beware of q2! J. Mol. Graph. Model., 20 (4) 269–276. 50. Rossafi B., Outahar F., Hammoudan I., Moumou M., Touti R., Benharref A., and Chtita S. (2025) Mechanism and stereoselectivity of epoxidation reaction of a β-himachalene derivative: Insights from dft, molecular docking, admet, and molecular dynamics investigations. J. Mol. Struct., 1320, 139664. 51. Kar S., and Roy K. (2010) Predictive toxicology using qsar: A perspective. J. Indian Chem. Soc., 87 (12) 1455. 52. Roy K., and Mitra I. (2012) On the use of the metric rm 2 as an effective tool for validation of qsar models in computational drug design and predictive toxicology. Mini Rev. Med. Chem., 12 (6) 491–504. 53. Roy, K., Das, R., Ambure, P., and Aher, R. (2016) Be aware of error measures Further. Chemometr. Intell. Lab. Syst., 152 (2016) 18–33 54. Dearden J. C. (2017) The history and development of quantitative structure-activity relationships (qsars): Addendum. Int. J. Quantit. Struct. Proper. Relation. (IJQSPR), 2 (2) 36–46. 55. El Rhabori, S., Alaqarbeh, M., Allouche, Y.E., Naanaai, L., El Aissouq, A., Bouachrine, M., Chtita, S., and Khalil, F. (2024). Exploring innovative strategies for identifying anti-breast cancer compounds by integrating 2D/3D-QSAR, molecular docking analyses, ADMET predictions, molecular dynamics simulations, and MM-PBSA approaches. J. Mol. Struct., 8 (2024) 100455. 56. Kanzouai, Y., Bouribab, A., El Moussaoui, A., Touhtouh, J., Laghmari, M., Bouzammit, R., Aflak, N., Boujdi, K., Chtita, S., and Benali, T. (2025). Design, synthesis and characterization of new amide-linked Chromone-Isoxazole Hybrids: In Vitro anti-bacterial and antioxidant evaluation, DFT calculations, ADMET profiling, docking and molecular dynamics simulation. J. Mol. Struct. 1325, 140972. 57. Zrinej J. (2022) Curcumin and derivatives against human colon cancer (hct-116). Computationnel. RHAZES: Green and Appl. Chem., 16, 83–102. 58. Chalkha M., Akhazzane M., Moussaid F. Z., Daoui O., Nakkabi A., Bakhouch M., Chtita S., Elkhattabi S., Housseini A. I., and El Yazidi M. (2022) Design, synthesis, characterization, in vitro screening, molecular docking, 3d-qsar, and adme-tox investigations of novel pyrazole derivatives as antimicrobial agents. New J. Chem., 46 (6) 2747–2760. 59. Bouamrane S., Khaldan A., Hajji H., El-Mernissi R., Alaqarbeh M., Alsakhen N., Maghat H., Ajana M. A., Sbai A., and Bouachrine M. (2023) In silico identification of 1, 2, 4-triazoles as potential candida albicans inhibitors using 3d-qsar, molecular docking, molecular dynamics simulations, and admet profiling. Mol. Diver., 27 (5) 2111–2132. 60. Daina A., Michielin O., and Zoete V. (2017) Swissadme: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. repor., 7 (1) 42717. 61. Dulsat J., López-Nieto B., Estrada-Tejedor R., and Borrell J. I. (2023) Evaluation of free online admet tools for academic or small biotech environments. Molecules, 28 (2) 776. 62. Pires D. E., Blundell T. L., and Ascher D. B. (2015) Pkcsm: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J. med. chem., 58 (9) 4066–4072. 63. Lipinski C. A. (2000) Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods, 44 (1) 235–249. 64. Trott O., and Olson A. J. (2010) Autodock vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. comput. chem., 31 (2) 455–461. 65. Cao H., Sun Y., Wang L., Zhao C., Fu J., and Zhang A. (2017) Understanding the microscopic binding mechanism of hydroxylated and sulfated polybrominated diphenyl ethers with transthyretin by molecular docking, molecular dynamics simulations and binding free energy calculations. Mol. Biosyst., 13 (4) 736–749. 66. Bouachrine M., Elmchichi L., El Aissouq A., Belhassan A., Zaki H., Ouammou A., and Lakhlifi T. (2021) Molecular docking, drug likeness studies and admet prediction of flavonoids as platelet-activating factor (paf) receptor binding. Chem. Rev. Lett., 4 (3) 145–152. 67. Fattouche M., Belaidi S., Abchir O., Al-Shaar W., Younes K., Al-Mogren M. M., Chtita S., Soualmia F., and Hochlaf M. (2024) Ann-qsar, molecular docking, admet predictions, and molecular dynamics studies of isothiazole derivatives to design new and selective inhibitors of hcv polymerase ns5b. Pharmaceuticals, 17 (12) 1712. 68. Fattouche M., Belaidi S., Ouassaf M., Chtita S., Al-Mogren M. M., and Hochlaf M. (2024) Computational studies of pyrimidine derivatives as inhibitors of human σ1 receptor using 3d-qsar analysis, molecular docking, admet properties and dft investigation. Chem. Phys. Impact., 8, 100463. 69. Jo S., Kim T., Iyer V. G., and Im W. (2008) Charmm‐gui: A web‐based graphical user interface for charmm. J. comput. chem., 29 (11) 1859–1865. 70. Van Der Spoel D., Lindahl E., Hess B., Groenhof G., Mark A. E., and Berendsen H. J. (2005) Gromacs: Fast, flexible, and free. J. comput. chem., 26 (16) 1701–1718. 71. Valdés-Tresanco M. S., Valdés-Tresanco M. E., Valiente P. A., and Moreno E. (2021) Gmx_mmpbsa: A new tool to perform end-state free energy calculations with gromacs. J. Chem. Theory Comput., 17 (10), 6281–6291. 72. Coley C. W., Thomas Iii D. A., Lummiss J. A., Jaworski J. N., Breen C. P., Schultz V., Hart T., Fishman J. S., Rogers L., and Gao H. (2019) A robotic platform for flow synthesis of organic compounds informed by ai planning. Science, 365 (6453) eaax1566. 73. Choi K., Lee Y., and Kim C. (2023) An in silico study for expanding the utility of cannabidiol in alzheimer’s disease therapeutic development. Int. J. Mol. Sci., 24 (21) 16013. 74. Ahmed F. Z., Ahmad A. A., and Kharazian B. (2023) A molecular dynamics study of the interaction between graphene as a carrier and gemcitabine as a chemotherapy. Zanco J. Pure Appl. Sci., 35 (1) 23–29.